The global Erleada market was valued at USD 2,999 million in 2024 and is projected to reach USD 6,166 million by 2033, growing at a CAGR of 7.99% from 2025 to 2033. Erleada, an androgen receptor inhibitor primarily used in the treatment of prostate cancer, particularly metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC), has...